Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus FOLFIRI in RAS-mutated mCRC
NCT05842525Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (CRC), sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05842525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842525.